This feature highlights changes in clinical research organizations’ personnel.
ACADIA Pharmaceuticals, Inc. has named Ponni Subbiah senior vice president, global head of medical affairs and chief medical officer. Subbiah recently served as CMO at Indivior.
Aeglea BioTherapeutics has expanded its senior management team with the appointment of Ravi M. Rao as chief medical officer and Michael C. Hanley as chief commercial officer. Rao was most recently vice president and head of global medical affairs at GlaxoSmithKline. Hanley was previously vice president and U.S. chief commercial officer for Esteve Pharamceuticals.
Michelle Graham has been appointed chief human resources officer at Albireo Pharma. Graham was most recently senior vice president and chief human resources officer with TESARO.
Arecor Limited has named Jim MacDonald-Clink vice president of business development. MacDonald-Clink was previously head of business development for Munipharma.
Biodesix has expanded its leadership team with the addition of Scott Hutton as chief executive officer. Hutton previously served as chief operating officer with the company.
Jeffery Blazevich has been named chief financial officer at BioDuro. Blazevich’s most recent appointment was CFO at Zest Dental Solutions.
Cerecin has named Bruce Morimoto vice president of drug development. Morimoto previously served as the vice president of drug development operation with Alkahest, Inc.
James O’Brien has been appointed chief financial officer at Cognition Therapeutics. O’Brien was most recently executive vice president of finance at Enzo Biochem.
CytoSorbents Corporation has appointed Zsolt Molnár medical director, Albert T. Leung as senior director of clinical affairs and Peter J. Nelson senior director of clinical affairs on the U.S. team. Molnár last served as head of the department of anesthesiology and intensive therapy at the University of Szeged in Hungary. Leung recently served as the chief medical officer for GlySure Ltd in the UK. Nelson was formerly an associate professor of medicine and regional clinical center principal investigator at the University of Washington Medical Center in Seattle.
Elysium Health, Inc. named Morgan Levine as head of Bioinformatics. Levine is currently a professor and aging researcher at the Yale School of Medicine.
Entasis Therapeutics has named David Altarac chief medical officer. Altarac was previously senior vice president and head of global regulatory affairs, global drug safety and research and development quality and compliance at Shire.
Nathan Dowden has been appointed chief operating officer at Entrada Therapeutics. Dowden previously served as senior vice president of strategy and corporate development at Rubius Therapeutics.
Niyati Patel has been appointed director of quality assurance and compliance at Experic. Patel was formerly the associate director of quality assurance at Extremity Medical, LLC.
Glympse Bio has appointed Tracey Dawson chief commercial officer and head of strategy. Dawson was most recently vice president of global product development and commercialization for the multiple sclerosis franchise at Biogen.
Imago BioSciences has named James D. Watson chief business officer. Watson formerly served as CBO at Sigilon Therapeutics and Alvine Pharmaceuticals.
Tom McCarthy has been named vice president of sales at Jopari Solutions. McCarthy was previously vice president of business development at One Call Care Management.
James Basta has been named chief legal officer and corporate secretary, as well as chief compliance officer at Kura Oncology. Basta was previously senior vice president and chief corporation counsel at Biogen.
Kenneth Chahine has been named chief executive officer at Laboratory for Advanced Medicine. Chahine formerly served as executive vice president and general manager of AncestryDNA.
Alfred Reszka has been appointed chief business officer at Lifescience Dynamics. Reszka previously held the position of executive director and head of strategic business intelligence at Merck & Co.
Minnetronix Medical, Inc. has named Jeremy Maniak chief executive officer. Maniak was most recently chief operating officer at Minnetronix.
Peter Li has been named chief executive officer at NiKang Therapeutics. Li was previously co-founder and founding CEO and chairman for Turning Point Therapeutics, Inc.
Ashley Winslow has been named chief scientific officer at Odylia Therapeutics. Winslow comes to Odylia from the Orphan Disease Center at the University of Pennsylvania where she was senior director of portfolio development and translational research.
Mark Varney has been named chief scientific officer at PsychoGenics. Varney previously served as CEO at Neurolixis.
Dario Eklund was named chief executive officer at Santhera. Eklund previously held the position of chief commercial officer with Vifor Pharma.
X4 Pharmaceuticals, Inc. has named Derek Meisner general counsel. Meisner most recently served as general counsel at Genocea Biosciences in Cambridge, Mass.
Todd N. Smith has been appointed president, chief executive officer and director at Zyla Life Sciences, effective immediately. Smith previously served as CEO and director of Iroko Pharmaceuticals, Inc.